The themes Quest Diagnostics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
売上構成比はthree months ended June 30, 2026の推計であり、提出された報告書の数字ではありません。
Routine and non-routine clinical laboratory tests
Tests of blood, urine and other samples, including common checks of blood counts, organ function, allergies and infections, as well as more specialized tests.
Advanced diagnostic tests
Specialized tests in areas such as cancer, genetics, brain health and autoimmune disease. Examples include blood tests for Alzheimer’s disease risk and Haystack testing for signs of remaining or returning cancer.
Anatomic pathology
Examination of tissue and cell samples to help diagnose cancer and other diseases.
Collaborative Lab Solutions
Services that help hospitals manage their laboratories, choose tests, control supply costs and use laboratory data.
QuestHealth.com
A website where people can buy health and wellness tests, with physician review of test orders and the option to discuss results with a physician.
ExamOne
Examinations, sample testing and information gathering that help life insurers assess insurance applicants.
Quest Diagnostics collects and tests blood, urine, tissue and other samples, then provides results that help healthcare professionals diagnose, monitor and treat medical conditions. It also performs tests that hospitals send to outside laboratories, helps hospitals run their own labs, and offers testing and data services to insurers and other organizations. It processed 244 million test requisitions (2025, high).
Quest Diagnostics Inc. 自身が米国証券取引委員会(SEC)に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
$259.690.0%11月13日 終値
2026年9月30日までの数値(2026年10月23日提出の10-Qより)
Quest Diagnostics performs medical tests on blood and other samples for doctors, hospitals, health plans and patients.
会社予想:2026会計年度の売上高$12.1B〜$12.1B — 前年同期比9.5%増
Grade A
株価の下の帯は各日付時点の評価で、その時点までに公開された書類だけで算出しています。
Quest Diagnostics Inc. の評価履歴 40 四半期のうち 2 四半期を表示しています。 残る 38 四半期は 2017年2月 まで遡ります。